Inflammation-Targeted Nanomedicines for the Treatment of Chronic Inflammatory Diseases and Cancer

Dear Colleagues,

Chronic inflammation is a key driver of numerous debilitating conditions, including inflammatory bowel disease, rheumatoid arthritis, chronic respiratory disorders, neurodegenerative diseases, and cardiovascular disease. Moreover, it plays a critical role in the development and progression of various cancers. The global incidence of chronic inflammatory disorders is rising, driven by increased life expectancy and population ageing as well as societal development and the interplay between genetic and environmental factors. Furthermore, the large socio-economic impact of chronic inflammation-driven disorders carries significant implications for both patients and society, demanding novel and comprehensive strategies to mitigate the consequences of chronic inflammation. Recent advances in nanomedicine have enabled the development of targeted, sustained, and responsive therapeutic platforms with the potential to overcome the limitations of conventional treatments. This Pharmaceutics Special Issue is dedicated to exploring nanotechnology-based delivery systems targeting the inflammatory niche that characterizes chronic inflammatory diseases and cancer.

As Guest Editors, we would like to encourage colleagues to submit their research work in the format of full papers or pertinent reviews, from diverse fields such as immunology, oncology, pharmaceutical sciences, nanomedicine and regenerative medicine, to develop innovative research that advances the clinical translation of next-generation therapies for chronic inflammatory disorders and cancer. We look forward to your contributions.

Dr. Rute Nunes
Dr. Flávia Castro
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.